The CCL20 and CCR6 axis in psoriasis.

Autor: Furue K; Department of Dermatology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan., Ito T; Department of Dermatology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan., Tsuji G; Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka, Japan., Nakahara T; Division of Skin Surface Sensing, Department of Dermatology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan., Furue M; Department of Dermatology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.; Research and Clinical Center for Yusho and Dioxin, Kyushu University Hospital, Fukuoka, Japan.; Division of Skin Surface Sensing, Department of Dermatology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Jazyk: angličtina
Zdroj: Scandinavian journal of immunology [Scand J Immunol] 2020 Mar; Vol. 91 (3), pp. e12846. Date of Electronic Publication: 2019 Nov 24.
DOI: 10.1111/sji.12846
Abstrakt: Psoriasis is a TNF-α/IL-23/IL-17A-mediated inflammatory skin disease that causes a significant socioeconomic burden in afflicted patients. IL-17A-producing immune cells, including Th17 cells, are crucial effector cells in the development of psoriasis. IL-17A stimulates epidermal keratinocytes to produce CCL20, which eventually recruits CCR6 + Th17 cells into the lesional skin. Thus, the CCL20/CCR6 axis works as a driving force that prepares an IL-17A-rich cutaneous milieu. In this review, we summarize the current research topics on the CCL20/CCR6 axis and the therapeutic intervention of this axis for psoriasis.
(© 2019 The Scandinavian Foundation for Immunology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje